Retrospective study of peptide receptor radionuclide therapy for Japanese patients with advanced neuroendocrine tumors.

ABSTRACT:

Background

Peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogs is an innovative treatment for advanced somatostatin-positive neuroendocrine tumors (NETs). PRRT cannot be performed in Japan because there is no approval or insurance cover so far.

Methods

We relied on foreign institutions to perform PRRT for Japanese patients with NETs. We retrospectively evaluated the safety and efficacy of PRRT. The inclusion criteria were pathologically confirmed well-differentiated NET and visible tumor uptake on pre-therapeutic somatostatin receptor scintigraphy. ¹⁷⁷ Lu-DOTA-TOC was used as the standard treatment, and patients received three infusions every 8 weeks. Until the end of 2017, combination treatment with ⁹⁰ Y and ¹⁷⁷

SUBMITTER: Kobayashi N 

PROVIDER: S-EPMC9292713 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature